Blood perfusion with polymyxin B immobilized columns in patients with COVID-19 requiring oxygen therapy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
31 May 2024
31 May 2024
Historique:
received:
15
12
2023
accepted:
28
05
2024
medline:
1
6
2024
pubmed:
1
6
2024
entrez:
31
5
2024
Statut:
epublish
Résumé
Extracorporeal blood purification with polymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP), is reported to be effective in treating COVID-19 pneumonitis with oxygen demand. This multicenter prospective study evaluated the efficacy and safety of PMX-DHP in oxygen-requiring patients with COVID-19 admitted between September 28, 2020, and March 31, 2022. The primary endpoint was the percentage of clinical improvement 15 days after treatment. The secondary endpoint was the percentage of worsened disease status. Data from the COVID-19 patient registry were used for the synthetic control group. The improvement rate on Day 15 did not differ between PMX-treated patients and controls; however, the deterioration rate was 0.38 times lower in the PMX-treated group, and the death rates on Day 29 were 0 and 11.1% in the PMX-treated and control groups, respectively. The PMX group showed a 0.73 times higher likelihood for reduced intensive care demand, as 16.7% of PMX-treated patients and 22.8% of controls worsened. After treatment blood oxygenation improved, urinary β2-microglobulin and liver-type fatty acid-binding protein showed significant decreases, and IL-6 decreased once during treatment but did not persist. In this study, PMX treatment effectively prevented the worsening of COVID-19 pathology, accompanied by improved oxygenation. PMX treatment to remove activated cells may effectively improve patient outcomes.
Identifiants
pubmed: 38822071
doi: 10.1038/s41598-024-63330-2
pii: 10.1038/s41598-024-63330-2
doi:
Substances chimiques
Polymyxin B
J2VZ07J96K
Oxygen
S88TT14065
Anti-Bacterial Agents
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
12550Subventions
Organisme : Japan Society for the Promotion of Science
ID : 23K07687
Organisme : Toray Industries
ID : R5DA-20-09-09、R5DA-21-02-09
Organisme : National Center for Global Health and Medicine
ID : 20A2008
Informations de copyright
© 2024. The Author(s).
Références
Ciceri, F. et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): An atypical acute respiratory distress syndrome working hypothesis. Crit. Care Resusc. 22, 95–97 (2020).
pubmed: 32294809
Ortega-Paz, L., Capodanno, D., Montalescot, G. & Angiolillo, D. J. Coronavirus disease 2019-associated thrombosis and coagulopathy: Review of the pathophysiological characteristics and implications for antithrombotic management. J. Am. Heart Assoc. 10, e019650. https://doi.org/10.1161/jaha.120.019650 (2021).
doi: 10.1161/jaha.120.019650
pubmed: 33228447
pmcid: 7955431
Gu, S. X. et al. Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 18, 194–209. https://doi.org/10.1038/s41569-020-00469-1 (2021).
doi: 10.1038/s41569-020-00469-1
pubmed: 33214651
Girardot, T., Schneider, A. & Rimmelé, T. Blood purification techniques for sepsis and septic AKI. Semin. Nephrol. 39, 505–514. https://doi.org/10.1016/j.semnephrol.2019.06.010 (2019).
doi: 10.1016/j.semnephrol.2019.06.010
pubmed: 31514914
Tang, L., Yin, Z., Hu, Y. & Mei, H. Controlling cytokine storm is vital in COVID-19. Front. Immunol. 11, 570993. https://doi.org/10.3389/fimmu.2020.570993 (2020).
doi: 10.3389/fimmu.2020.570993
pubmed: 33329533
pmcid: 7734084
Katagiri, D. et al. Continuous renal replacement therapy for a patient with severe COVID-19. Blood Purif. https://doi.org/10.1159/000508062 (2020).
doi: 10.1159/000508062
pubmed: 32526746
Yokoyama, T. et al. A case of severe ARDS caused by novel swine-origin influenza (A/H1N1pdm) virus: A successful treatment with direct hemoperfusion with polymyxin B-immobilized fiber. J. Clin. Apher. 25, 350–353. https://doi.org/10.1002/jca.20252 (2010).
doi: 10.1002/jca.20252
pubmed: 20623785
Allen, R. J. et al. Genetic overlap between idiopathic pulmonary fibrosis and COVID-19. Eur. Respir. J. 60, 2103132. https://doi.org/10.1183/13993003.03132-2021 (2022).
doi: 10.1183/13993003.03132-2021
pubmed: 35595312
Oishi, K. et al. Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B-immobilized fiber column: A retrospective analysis. Intern. Med. 55, 3551–3559. https://doi.org/10.2169/internalmedicine.55.6056 (2016).
doi: 10.2169/internalmedicine.55.6056
pubmed: 27980253
pmcid: 5283953
Furusawa, H., Sugiura, M., Mitaka, C. & Inase, N. Direct hemoperfusion with polymyxin B-immobilized fibre treatment for acute exacerbation of interstitial pneumonia. Respirology 22, 1357–1362. https://doi.org/10.1111/resp.13054 (2017).
doi: 10.1111/resp.13054
pubmed: 28440556
Oishi, K. et al. Improved prognostic prediction by combination of early initiation of polymyxin B hemoperfusion with modified gender-age-physiology index in acute exacerbation of idiopathic pulmonary fibrosis. Blood Purif. 51, 485–491. https://doi.org/10.1159/000518705 (2022).
doi: 10.1159/000518705
pubmed: 34518460
Katagiri, D. et al. Direct hemoperfusion using a polymyxin B-immobilized polystyrene column for COVID-19. J. Clin. Apher. 36, 313–321. https://doi.org/10.1002/jca.21861 (2021).
doi: 10.1002/jca.21861
pubmed: 33325084
De Rosa, S., Cutuli, S. L., Ferrer, R., Antonelli, M. & Ronco, C. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry. Artif. Organs 45, E187-e194. https://doi.org/10.1111/aor.13900 (2021).
doi: 10.1111/aor.13900
pubmed: 33377184
Ishiwari, M. et al. Polymyxin B haemoperfusion treatment for respiratory failure and hyperferritinaemia due to COVID-19. Respirol. Case Rep. 8, e00679. https://doi.org/10.1002/rcr2.679 (2020).
doi: 10.1002/rcr2.679
pubmed: 33163186
pmcid: 7604553
Kuwana, T. et al. The characteristics of patients with severe COVID-19 pneumonia treated with direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP). Infect. Drug Resist. 15, 4819–4828. https://doi.org/10.2147/idr.S374920 (2022).
doi: 10.2147/idr.S374920
pubmed: 36043160
pmcid: 9420440
Terada-Hirashima, J. et al. Efficacy and safety of direct hemoperfusion using polymyxin B-immobilized polystyrene column for patients with COVID-19: Protocol for an exploratory study. JMIR Res. Protoc. 11, e37426. https://doi.org/10.2196/37426 (2022).
doi: 10.2196/37426
pubmed: 36126219
pmcid: 9674082
Matsunaga, N. et al. Clinical epidemiology of hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan: Report of the COVID-19 registry Japan. Clin. Infect. Dis. 73, e3677–e3689. https://doi.org/10.1093/cid/ciaa1470 (2021).
doi: 10.1093/cid/ciaa1470
pubmed: 32986793
Cao, B. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2001282 (2020).
doi: 10.1056/NEJMoa2001282
pubmed: 33356051
pmcid: 7377062
Mise, K. et al. Prognostic value of tubulointerstitial lesions, urinary N-acetyl-beta-d-glucosaminidase, and urinary beta2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy. Clin. J. Am. Soc. Nephrol. CJASN 11, 593–601. https://doi.org/10.2215/cjn.04980515 (2016).
doi: 10.2215/cjn.04980515
pubmed: 26801478
Katagiri, D. et al. Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann. Thorac. Surg. 93, 577–583. https://doi.org/10.1016/j.athoracsur.2011.10.048 (2012).
doi: 10.1016/j.athoracsur.2011.10.048
pubmed: 22269724
Araujo, J. C. et al. Comparison of hexamethyldisilazane and critical point drying treatments for SEM analysis of anaerobic biofilms and granular sludge. J. Electron Microsc. 52, 429–433. https://doi.org/10.1093/jmicro/52.4.429 (2003).
doi: 10.1093/jmicro/52.4.429
Sasako, T. et al. Deletion of skeletal muscle Akt1/2 causes osteosarcopenia and reduces lifespan in mice. Nat. Commun. 13, 5655. https://doi.org/10.1038/s41467-022-33008-2 (2022).
doi: 10.1038/s41467-022-33008-2
pubmed: 36198696
pmcid: 9535008
Peerapornratana, S. et al. Endotoxin adsorbent therapy in severe COVID-19 pneumonia. Blood Purif. 51, 47–54. https://doi.org/10.1159/000515628 (2022).
doi: 10.1159/000515628
pubmed: 33857940
Leisman, D. E. et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 8, 1233–1244. https://doi.org/10.1016/s2213-2600(20)30404-5 (2020).
doi: 10.1016/s2213-2600(20)30404-5
pubmed: 33075298
pmcid: 7567529
Supady, A. et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): A single centre, open-label, randomised, controlled trial. Lancet Respir. Med. 9, 755–762. https://doi.org/10.1016/s2213-2600(21)00177-6 (2021).
doi: 10.1016/s2213-2600(21)00177-6
pubmed: 34000236
pmcid: 8121541
Dellinger, R. P. et al. Effect of targeted polymyxin b hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: The EUPHRATES randomized clinical trial. Jama 320, 1455–1463. https://doi.org/10.1001/jama.2018.14618 (2018).
doi: 10.1001/jama.2018.14618
pubmed: 30304428
pmcid: 6233793
Klein, D. J. et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: A post hoc analysis of the EUPHRATES trial. Intens. Care Med. 44, 2205–2212. https://doi.org/10.1007/s00134-018-5463-7 (2018).
doi: 10.1007/s00134-018-5463-7
Kuwana, T. et al. PMX-DHP therapy for dyspnea and deoxygenation in severe COVID-19 pneumonia: A case series. Infect. Drug Resist. 14, 1305–1310. https://doi.org/10.2147/idr.S299023 (2021).
doi: 10.2147/idr.S299023
pubmed: 33854342
pmcid: 8040694
Katagiri, D., Izumi, S. & Takano, H. When should polymyxin B-immobilized polystyrene column be introduced to improve COVID-19 prognosis?. Ther. Apher. Dial. 26, 550–551. https://doi.org/10.1111/1744-9987.13825 (2022).
doi: 10.1111/1744-9987.13825
pubmed: 35247232
pmcid: 9111317
Katagiri, D. et al. Evaluation of coronavirus disease 2019 severity using urine biomarkers. Crit. Care Explor. 2, e0170. https://doi.org/10.1097/cce.0000000000000170 (2020).
doi: 10.1097/cce.0000000000000170
pubmed: 32766565
pmcid: 7402421
Noiri, E., Katagiri, D., Asai, Y., Sugaya, T. & Tokunaga, K. Urine oxygenation predicts COVID-19 risk. Clin. Exp. Nephrol. https://doi.org/10.1007/s10157-023-02456-5 (2024).
doi: 10.1007/s10157-023-02456-5
pubmed: 38400935
Katagiri, D. et al. Urinary L-type fatty acid-binding protein predicts oxygen demand of COVID-19 in initially mild cases. Crit. Care Explor. 5, e0873. https://doi.org/10.1097/cce.0000000000000873 (2023).
doi: 10.1097/cce.0000000000000873
pubmed: 36910457
pmcid: 10005822
Abe, S. et al. Neutrophil adsorption by polymyxin B-immobilized fiber column for acute exacerbation in patients with interstitial pneumonia: A pilot study. Blood Purif. 29, 321–326. https://doi.org/10.1159/000287232 (2010).
doi: 10.1159/000287232
pubmed: 20185904
Suissa, S. Single-arm trials with historical controls: Study designs to avoid time-related biases. Epidemiology 32, 94–100. https://doi.org/10.1097/ede.0000000000001267 (2021).
doi: 10.1097/ede.0000000000001267
pubmed: 33009252